SIMULATIONS PLUS WKN: 924294 ISIN: US8292141053 Kürzel: SLP Forum: Aktien Thema: Hauptdiskussion

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration’s draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidance encourages reduced reliance on animal studies and elevates mechanistic understanding, pharmacokinetics, and integrated weight-of-evidence (WoE) assessments for nonclinical decision-making. “The FDA’s draft guidance signals a clear regulatory mandate towards mechanistic, model-informed science, and Simulations Plus is uniquely positioned to help clients respond with confidence,” said Shawn O’Connor, Chief Executive Officer of Simulations Plus. “Our scientific engines, workflows, and cross-disciplinary capabilities have supported these integrated approaches for years.”

…

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Zahlen Q3 haben enttäuscht

Hallo, weiß jemand warum die Aktie auf einmal 15% nachgibt?

Scheint vergleichbare mit SDGR zu sein?

Euer 🌰

Volumen extrem gering in Europa! Besser bei Nasdaq kaufen

Noch nicht viel los hier. Im Aktionär heute eine Seite... Bin gespannt wie es hier weitergeht.

Watch

Mega